ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Press Release
Ocumension Therapeutics Announces 2023 Interim Results
Aug 24, 2023 23:35 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today.
More info..
Ocumension Therapeutics Announces 2022 Annual Results
Mar 30, 2023 22:29 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today.
More info..
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
Mar 13, 2023 18:30 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023.
More info..
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
Feb 14, 2023 10:57 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022").
More info..
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
Feb 03, 2023 10:01 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.
More info..
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
Feb 01, 2023 10:00 JST
Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop)
More info..
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
Jan 30, 2023 11:38 JST
Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group.
More info..
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
Mar 20, 2021 10:10 JST
The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today.
More info..
1
Latest Release
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
Construction Begins on New Toyota Tokyo Head Office in Shinagawa, to Open in FY2030
May 27, 2025 14:31 JST
JCB partners with PayXpert to expand in-store card acceptance for international shoppers and travellers coming to Europe and in the UK
May 27, 2025 12:00 JST
JCB Collaborates with Noage International to Expand Advanced Medical Tourism Program in Japan for Affluent Indonesians
May 27, 2025 10:00 JST
Ministry of Energy of Uzbekistan and MHI Sign MOU to Conduct Joint Study of Decarbonization Strategy for Uzbekistan
May 27, 2025 09:49 JST
Fujitsu launches second corporate venture capital fund to drive innovation and achieve a sustainable society
May 26, 2025 18:27 JST
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
MHI Conducts Flight Test for Hybrid-Type Medium-Sized UAV
May 22, 2025 13:35 JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21, 2025 15:00 JST
New RAV4 Makes World Premiere in Japan
May 21, 2025 14:09 JST
Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer
May 21, 2025 14:00 JST
MHI Marine Machinery Begin Demonstration Testing of Methane Oxidation Catalyst System for Marine LNG Engines
May 20, 2025 13:51 JST
MHI Launches 'Prismo,' a New Brand Eco-Friendly Next-Generation AGT
May 19, 2025 16:14 JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16, 2025 17:21 JST
More Latest Release >>